MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Teniposide

CAS No. : 29767-20-2

MCE 国际站：Teniposide

产品活性：Teniposide 是一种足叶草毒素衍生物，是拓扑异构酶 II (topoisomerase II) 的抑制剂，同时为一种化疗剂。

研究领域：Cell Cycle/DNA Damage

作用靶点：Topoisomerase

In Vitro: Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC₅₀ of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC₅₀ of 1.3 ± 0.34 μg/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC₅₀ decreases from 5.86 ± 0.36 μg/mL to 2.90 ± 0.35 μg/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2.

In Vivo: Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice.

相关产品：Natural Product-like Compound Library  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Tumorigenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Chemotherapy Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Gepotidacin  |  Topoisomerase IV inhibitor 2  |  Phenoxodiol  |  Topotecan hydrochloride hydrate  |  NHC-triphosphate tetraammonium  |  Berberine  |  Levofloxacin sodium  |  TAS-103 dihydrochloride  |  Ciprofloxacin  |  Mitoxantrone diacetate  |  Murrayanol  |  Gimatecan  |  Camptothecin  |  EGFR-IN-57  |  SW044248  |  Topoisomerase I/II inhibitor 4  |  NHC-diphosphate triammonium  |  Betulinic acid  |  ICRF-196  |  3,6-Diamino-9(10H)-acridone  |  Epirubicin  |  12-Ethyl-9-hydroxycamptothecin  |  Topoisomerase II inhibitor 3  |  Becatecarin  |  Pixantrone hydrochloride  |  Datopotamab deruxtecan  |  Isosteviol

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。